Moffitt logo

Clinical Trials Search

Clinical Trial 19985

Cancer Type: Gastrointestinal Tumor
Interventions:Gemzar (gemcitabine); XERMELO; cisplatin; gemcitabine

Study Type: Treatment
Phase of Study: Phase II
Investigators:

  • Richard Kim

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) plus First-line Chemotherapy in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Summary

The purpose of this study is to test whether Xermelo® (500 mg given 3 times daily) when given with chemotherapy that is used as a standard treatment for this tumor type (cisplatin [cis]/gemcitabine [gem] chemotherapy [given twice in a 21-day cycle]) will have an effect on the growth of BTC tumor(s).

Objective

The primary objective of the study is to assess the safety and efficacy (progression-free survival rate at Month 6) of XERMELO in combination with cisplatin (cis) plus gemcitabine (gem) To assess the effect of study treatment on the following: Overall survival (OS) OS rate at Months 6 and 12 PFS rate at Month 12 and median PFS Disease control rate (DCR); defined as complete response (CR) + partial response (PR) + stable disease (SD) at Months 6 and 12 and End of Study (EOS) Objective response rate (ORR) defined as CR + PR at Months 6 and 12 and EOS Local radiologists assessment of PFS, ORR, and DCR Change from Baseline in plasma 5-hydroxyindoleacetic acid (5-HIAA) and serum carbohydrate antigen 19-9 (CA 19-9) at Months 6 and 12 and EOS Change from Baseline in body weight at Months 6 and 12 and EOS Change from Baseline in serum albumin at Months 6 and 12 and EOS

Inclusion Criteria

  • Male or female adults, ≥18 years of age. Patients of childbearing potential must agree to use an adequate method of contraception during the study and for 30 days after the last dose of XERMELO
  • Histopathologically or cytologically-confirmed, unresectable, locally advanced, recurrent, or metastatic biliary tract cancer (BTC)
  • Naïve to tumor-directed therapy in locally advanced, unresectable, or metastatic setting
  • Measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Plans to initiate treatment with 1L therapy (cisplatin plus gemcitabine)
  • Ability to provide written informed consent prior to participation in any study-related procedure

  • Exclusion Criteria

  • Prior exposure to XERMELO, telotristat ethyl, telotristat etiprate, LX1032, or LX1606
  • Primary tumor site in the ampulla of Vater
  • Treatment with photodynamic therapy for localized disease or to relieve biliary obstruction in the presence of metastatic disease within the past 30 days
  • Hematology laboratory values of: a. Absolute neutrophil count (ANC) ≤1,500 cells/mm^3; or b. Platelets ≤100,000 cells/mm^3; or c. Hemoglobin (Hgb) ≤9 g/dL; or d. White blood count (WBC) ≤3,000 cells/mm^3
  • Hepatic laboratory values of aspartate aminotransferase (AST) or alanine aminotransferase (ALT): a. >5 x upper limit of normal (ULN) if patient has documented history of hepatic metastases; or b. >2.5 x ULN if no liver metastases are present
  • Serum albumin >Total bilirubin >1.5 x ULN or >1.5 mg/dL
  • Prothrombin time (PT) or international normalized ratio (INR) >1.5 x ULN
  • Serum creatinine or serum urea >1.5 x ULN
  • Estimated glomerular filtration rate (eGFR) >Positive pregnancy test, pregnant, or breastfeeding
  • Any other clinically significant laboratory abnormality that would compromise patient safety or the outcome of the study
  • Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
  • Myocardial infarction within the past 6 months
  • Active bleeding diathesis
  • Life expectancy ≤3 months
  • Current complaints of persistent constipation or history of chronic constipation, bowel obstruction or fecaloma within the past 6 months
  • Receiving chronic treatment with corticosteroids ≥5 mg of prednisone per day (or equivalent) or other immunosuppressive agent(s)
  • History and/or uncontrolled hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV)-1 or HIV-2
  • History of substance or alcohol abuse within the past 2 years
  • History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose malabsorption
  • History of malignancy or active treatment for malignancy within 5 years
  • Receipt of live, attenuated vaccine or close contact with someone who has received a live, attenuated vaccine within the past 1 month
  • Receipt of any investigational agent or study treatment (ie, any treatment or therapy not approved by the FDA for the treatment of BTC) within the past 30 days
  • Receipt of any protein or antibody-based therapeutic agents within the past 3 months
  • Treatment with any tumor-directed therapy within the past 6 months with curative intent
  • Existence of any surgical or medical condition that, in the judgment of the Investigator, might compromise patient safety or the outcome of the study
  • Presence of any clinically significant findings (relative to the patient population) during review of medical history or upon physical exam that, in the Investigator's or Medical Monitor's opinion, would compromise patient safety or the outcome of the study
  • Evidence of brain metastases
  • Unable or unwilling to communicate or cooperate with the Investigator for any reason
  • Employee of Sponsor or clinical site, or relative of any member of a clinical site's staff